83 related articles for article (PubMed ID: 18399770)
1. Plasma exchanges overcome persistent iodine overload to enable 131I ablation of differentiated thyroid carcinoma.
Toubert ME; Dib-Deperrest A; Houzé P; Parquet N; Hindie E; Moretti JL
Thyroid; 2008 Apr; 18(4):469-72. PubMed ID: 18399770
[TBL] [Abstract][Full Text] [Related]
2. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
[TBL] [Abstract][Full Text] [Related]
3. Treatment for microcarcinoma of the thyroid--clinical experience.
Küçük NO; Tari P; Tokmak E; Aras G
Clin Nucl Med; 2007 Apr; 32(4):279-81. PubMed ID: 17413573
[TBL] [Abstract][Full Text] [Related]
4. Hürthle cell carcinoma: a clinicopathological study of thirteen cases.
Ozlem Küçük N; Kulak H; Tokmak E; Tar P; Ibiş E; Aras G
Nucl Med Commun; 2006 Apr; 27(4):377-9. PubMed ID: 16531925
[TBL] [Abstract][Full Text] [Related]
5. The impact of iodinated contrast agent administered during preoperative computed tomography scan on body iodine pool in patients with differentiated thyroid cancer preparing for radioactive iodine treatment.
Sohn SY; Choi JH; Kim NK; Joung JY; Cho YY; Park SM; Kim TH; Jin SM; Bae JC; Lee SY; Chung JH; Kim SW
Thyroid; 2014 May; 24(5):872-7. PubMed ID: 24295076
[TBL] [Abstract][Full Text] [Related]
6. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
[TBL] [Abstract][Full Text] [Related]
7. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal.
Elisei R; Schlumberger M; Driedger A; Reiners C; Kloos RT; Sherman SI; Haugen B; Corone C; Molinaro E; Grasso L; Leboulleux S; Rachinsky I; Luster M; Lassmann M; Busaidy NL; Wahl RL; Pacini F; Cho SY; Magner J; Pinchera A; Ladenson PW
J Clin Endocrinol Metab; 2009 Nov; 94(11):4171-9. PubMed ID: 19850694
[TBL] [Abstract][Full Text] [Related]
8. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
[TBL] [Abstract][Full Text] [Related]
9. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation?
Mazzaferri EL; Kloos RT
J Clin Endocrinol Metab; 2002 Apr; 87(4):1490-8. PubMed ID: 11932270
[TBL] [Abstract][Full Text] [Related]
10. Prognostic implication of thyroglobulin and quantified whole body scan after initial radioiodine therapy on early prediction of ablation and clinical response for the patients with differentiated thyroid cancer.
Lim I; Kim SK; Hwang SS; Kim SW; Chung KW; Kang HS; Lee ES
Ann Nucl Med; 2012 Dec; 26(10):777-86. PubMed ID: 22869417
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.
Vianello F; Mazzarotto R; Mian C; Lora O; Saladini G; Servodio O; Basso M; Pennelli G; Pelizzo MR; Sotti G
Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):162-8. PubMed ID: 21411300
[TBL] [Abstract][Full Text] [Related]
12. Cumulative doses of adjunct 131I treatment depend on location of residual thyroid tissue after total thyroidectomy in differentiated thyroid cancer.
Saint-Vil D; Emran MA; Lambert R; Alos N; Turpin S; Huot C
J Pediatr Surg; 2007 May; 42(5):853-6. PubMed ID: 17502198
[TBL] [Abstract][Full Text] [Related]
13. International Czech and Slovak cooperation in the treatment of patients with differentiated thyroid cancer.
Kraft O; Reznák I
Nucl Med Rev Cent East Eur; 2006; 9(1):84-8. PubMed ID: 16791814
[TBL] [Abstract][Full Text] [Related]
14. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.
Tsang RW; Brierley JD; Simpson WJ; Panzarella T; Gospodarowicz MK; Sutcliffe SB
Cancer; 1998 Jan; 82(2):375-88. PubMed ID: 9445196
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of thyroglobulin after thyroidectomy before ablative radioiodine therapy in thyroid cancer.
Grünwald F; Menzel C; Fimmers R; Zamora PO; Biersack HJ
J Nucl Med; 1996 Dec; 37(12):1962-4. PubMed ID: 8970514
[TBL] [Abstract][Full Text] [Related]
16. A randomized clinical trial comparing 50mCi and 100mCi of iodine-131 for ablation of differentiated thyroid cancers.
Zaman Mu; Toor R; Kamal S; Maqbool M; Habib S; Niaz K
J Pak Med Assoc; 2006 Aug; 56(8):353-6. PubMed ID: 16967785
[TBL] [Abstract][Full Text] [Related]
17. The continuous debate in literature about the usage of iodine-131 dosing for the ablation of thyroid remnants and metastases.
De Klerk JM; Oyen WJ
Minerva Endocrinol; 2009 Mar; 34(1):57-69. PubMed ID: 19209128
[TBL] [Abstract][Full Text] [Related]
18. Differentiated thyroid carcinoma in children and adolescents: a 37-year experience in 85 patients.
Dottorini ME; Vignati A; Mazzucchelli L; Lomuscio G; Colombo L
J Nucl Med; 1997 May; 38(5):669-75. PubMed ID: 9170425
[TBL] [Abstract][Full Text] [Related]
19. Radioiodine therapy for papillary and follicular thyroid carcinoma.
Klain M; Ricard M; Leboulleux S; Baudin E; Schlumberger M
Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S479-85. PubMed ID: 12192549
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy.
Vassilopoulou-Sellin R; Schultz PN; Haynie TP
Cancer; 1996 Aug; 78(3):493-501. PubMed ID: 8697396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
